We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
37,700 women have purchased hormone replacement therapy (HRT) prescription prepayment certificates (PPC) following the launch, saving over £1.13 million.
Around 400,000 women across England will get better access to menopause support - saving hundreds of pounds and making treatment more accessible.
From 1 April 2023, women in England will be able to access cheaper hormone replacement therapy (HRT) to help with menopause symptoms.
The government has issued serious shortage protocols (SSPs) to limit dispensing to 3 months’ supply for 3 HRT products to ensure continued access.
The government has announced that Madelaine McTernan CB has been appointed as head of the newly formed HRT taskforce to address issues in the supply chain.
St John’s wort interacts with hormonal contraceptives reducing the effectiveness and increasing the risk of unplanned pregnancy.
Employment Tribunal decision.
Risk of meningioma with cyproterone acetate increases with increasing cumulative dose. Use of cyproterone is contraindicated in patients with previous or current meningioma (for all indications) and should only be considered for control of libido in severe hypersexuality or paraphilias...
Before prescribing hormone-replacement therapy, healthcare professionals should consider carefully the potential benefits and risks for every woman
Head of the HRT Taskforce Madelaine McTernan presents key recommendations for future management of hormone replacement therapy (HRT) supply.
Public call for evidence launched relating to the use of hormonal pregnancy tests.
A group of independent experts will review all evidence provided; we will publish a report of the group’s findings.
Government action to cut the cost of repeatable HRT prescriptions and a new Menopause Taskforce means women experiencing the menopause will be better supported.
If a patient reports persistent symptoms when switching between different levothyroxine tablet formulations, consider consistently prescribing a specific product known to be well tolerated by the patient. If symptoms or poor control of thyroid function persist (despite adhering to a...
New data have confirmed that the risk of breast cancer is increased during use of all types of HRT, except vaginal estrogens, and have also shown that an excess risk of breast cancer persists for longer after stopping HRT than...
Today (17 January 2019) the Government Equalities Office is launching a call for evidence on the experiences of people who have variations in sex characteristics.
An Expert Working Group (EWG) of the UK’s Commission on Human Medicines (CHM) has published their report on the use of hormone pregnancy tests (HPTs) and adverse effects relating to pregnancy including possible birth defects.
Women across the country to benefit from better access to care for essential services for menstrual problems, contraception, pelvic pain and menopause care.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).